Breakthrough Company????? Endovasc ENDV Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breakthrough Company????? Endovasc ENDV

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Abe Bleich who wrote ()	4/28/1999 7:30:00 PM
From: NY_Know	Read Replies (1) of 94

News out today: News April 28, 18:00 Eastern Time MONTGOMERY, TEXAS (April 28) BUSINESS WIRE -April 28, 1999--Endovasc Ltd. Inc. (OTC BB: ENDV) today announced that Baylor College of Medicine presented new data at the Experimental Biology Meeting last week on the efficacy of Prostaglandin E-1 in inhibiting the migration of vascular smooth muscle cell (thought to be the main cause of reblockage of blood vessels) by disruption of stress fibers and adhesion plaques. Prof. Charles Seidel's (Baylor's Section of Medicine - Cardiovascular Sciences) data was further substantiated by Buerke and co-workers from Johannes Gutenberg-University in Mainz, Germany. Their independent work confirmed (at the same meeting) that Lipo-PGE-1 significantly reduced intima proliferation and smooth muscle cell proliferation in the animal model. "What this means," said company spokesman Dr. David P. Summers, "is that if this effect continues to be maintained in the human model, then we have a home run product within a $2 billion market. We should have early indications of its success in humans by the beginning of the third quarter. If approval comes from the FDA quickly, we could easily niche out $200 million from this market by the end of three years." About the company Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in the generic form. The company's products and processes are covered by patents and trade secrets for competing in a $2 billion market. The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. More supporting clinical trial research. We are getting closer... NY_Know

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next